Title: Clinical Characteristics and Outcomes of Laboratory-Confirmed SARS-CoV-2 Cases Infected with Omicron subvariants and XBB recombinant variant

Authors: Rajesh Karyakarte¹, Rashmita Das¹, Sonali Dudhate¹, Jeanne Agarasen¹, Praveena Pillai¹, Priyanka Chandankhede¹, Rutika Labshetwar¹, Yogita Gadiyal¹, Mansi Rajmane¹, Preeti Kulkarni¹, Safanah Nizarudeen¹, Suvarna Joshi¹, Varsha Potdar², Krishanpal Karmodiya³

¹ Department of Microbiology, Byramjee Jeejeebhoy Government Medical College, Pune, Maharashtra, India

² ICMR-National Institute of Virology, Pune, Maharashtra, India

³ Department of Biology, Indian Institute of Science Education and Research, Dr Homi Bhabha Road, Pashan, Pune, Maharashtra, India

Corresponding Author: Dr Rajesh Karyakarte

ABSTRACT

Background: SARS-CoV-2 has evolved to produce new variants causing successive waves of infection. Currently, six variants are being monitored by the World Health Organization that are replacing BA.5. These include BF.7 (BA.5 + R346T in spike), BQ.1 (and BQ.1.1, with BA.5 + R346T, K444T, N460K mutations in spike), BA.2.75 (including BA.2.75.2 and CH.1.1), and XBB (including XBB.1.5). BQ.1 and XBB variants are more immune evasive and have spread quickly throughout the world. With the concern of the potential severity of infections caused by these variants, the present study describes the clinical characteristics and outcomes of these major variants in Maharashtra. Material and Methods: A total of 1141 Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR) positive SARS-CoV-2 samples, with a cycle threshold value (Ct) less than 25, were processed for SARS-CoV-2 whole genome sequencing between 10th July 2022 and 12th January 2023. All corresponding demographic and clinical data were recorded and analysed using Microsoft[®] Excel and Epi Info[™]. **Results:** Out of 1141 samples sequenced, BA.2.75* (63.78%) was the predominant Omicron variant, followed by the XBB* (18.88%), BA.2.38* (4.94%), BA.5* (4.06%), BA.2.10* (3.51%) and BQ.1* (1.65%). A total of 540 cases were contacted telephonically, of which 494 (91.48%) were symptomatic with mild symptoms. Fever (77.73%) was the most common symptom, followed by cold (47.98%), cough (42.31%), myalgia and fatigue (18.83%). Of the 540 cases, 414 (76.67%) cases recovered at home, and 126 (23.33%) were institutionally guarantined/hospitalised. Among the homeisolated and hospitalised cases, 416 (99.76%) and 108 (87.80%), respectively, recovered with symptomatic treatment, while one (0.24%) and 15 (12.20%), respectively, succumbed to the disease. In all, 491 (90.93%) cases were vaccinated with at least one dose of the COVID-19 vaccine, 41 (7.59%) were unvaccinated, and for 08 (1.48%), vaccine data was not available. **Conclusion:** The current study indicates that the XBB* variant is causing mild disease in India. However, as XBB* possess both immune-escape and infectivity-enhancing mutations, it has the potential to spread to other parts of the world rapidly.

KEYWORDS: SARS-CoV-2, BA.2.10*, BA.2.38*, BA.2.75*, BA.5*, BQ.1*, XBB*, XBB.1.5

ARTICLE

1. INTRODUCTION

The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has evolved continuously to give rise to new variants driving successive waves of infection. (1) Since its first emergence in November 2021, the Omicron variant of concern (VOC) has become the most widespread and dominant variant globally. Currently, BA.5 and its descendant lineages are the dominant variants, followed by BA.2.75 and its subvariants (as of 1st January 2023). (2) With a swarm of variants emerging and competing in the "variant soup" (3), there are four subvariants which are replacing the BA.5 descendent lineages and are under monitoring by the World Health Organization. (2) These include BF.7 (BA.5 + R346T in spike), BQ.1 (and BQ.1.1, with BA.5 + R346T, K444T, N460K mutations in spike), BA.2.75 (including BA.2.75.2 and CH.1.1), and XBB (including XBB.1.5). (2) BQ.1, a sub-lineage of BA.5, was first identified in Nigeria in early July 2022. There are 80 Pango lineages associated with the BQ.1* variant (* indicates the lineage and its sub-lineages), which have spread dramatically to Europe, South America, North America, and Africa. (4,5) XBB is a recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e., BJ.1 and BM.1.1.1, respectively, with a breakpoint in S1. It was first identified in mid-August 2022 and is suggested to have emerged around the Indian subcontinent. (5) XBB and its sub-lineages have spread quickly and have become dominant in India, Bangladesh, Malaysia, Singapore, and other parts of Asia. (5,6) Recently, a subvariant of XBB.1, the XBB.1.5 variant, has rapidly spread and has been detected in at least 46 countries and 49 states in the United States of America. (7) As these variants continue to evolve and diversify, they are of particular interest, as they are more immune evasive and expand rapidly due to additional mutations in their spike protein. There is evidence that these SARS-CoV-2 variants may further reduce the effectiveness of current COVID-19 vaccines and monoclonal antibody treatments. (5)

For an effective pandemic response, it is essential to understand the range of illnesses associated with these new strains. There are concerns about the potential severity of infections caused by these variants due to multiple mutations in their spike protein, which may affect their ability to enter cells and escape the immune system. (8) Therefore, the

present study describes the clinical characteristics and outcomes of the major variants identified during the community surveillance of SARS-CoV-2 in Maharashtra.

2. MATERIAL AND METHODS

The present study was conducted as part of the Indian SARS-CoV-2 Genomics Consortium (INSACOG) sequencing activity in Maharashtra to monitor genomic variations in the virus and to study its epidemiological trends. The study protocol for SARS-CoV-2 whole genome sequencing was reviewed and approved by the Institutional Ethics Committee at Byramjee Jeejeebhoy Government Medical College (BJGMC), Pune, Indian Council of Medical Research- National Institute of Virology (ICMR-NIV), Pune and Indian Institute of Science, Education and Research (IISER), Pune.

2.1 Sample Acquisition

Samples from several RT-PCR swab collection and testing centres in various districts of Maharashtra and its neighbouring states were sent to BJGMC, ICMR-NIV and IISER, Pune, for whole genome sequencing.

Respiratory specimens, including nasopharyngeal and oropharyngeal swabs, positive for SARS-CoV-2 infection, were collected in Viral Transport Medium (VTM). These samples were transported to the sequencing laboratory in triple packaging, maintaining the cold chain, and stored at -80°C. According to government instructions and INSACOG, 5% of the samples from positive cases with a Ct value less than 25, including clusters, vaccine breakthrough infections, cases with mild and moderate symptoms, and hospitalised and deceased cases, were processed.

2.2 RNA Extraction, Library Preparation, Next Generation Sequencing, and Lineage Analysis

Total RNA was extracted from respiratory specimens using the MagMaxTM Viral/Pathogen nucleic acid extraction kit (ThermoFisher Scientific, Waltham, MA, USA) on an automated extraction system, KingFisher Flex (ThermoFisher, Waltham, MA, USA), following the manufacturer's instructions. Nucleic acid was eluted in 50 μ L of elution buffer, and the RNA was quantified with the Qubit RNA High Sensitivity Kit using the Qubit[®] 2.0 Fluorometer (ThermoFisher Scientific, Waltham, MA, USA). This RNA was used for library preparation for sequencing.

Libraries for SARS-CoV-2 sequencing were prepared using the Rapid Barcoding Kit (RBK110.96) and Midnight RT-PCR Expansion Kits (EXP001) (BJGMC, Pune), Ion 540TM chip and the Ion Total RNA-Seq kit v2.0 (ThermoFisher Scientific, Waltham, MA, USA) (ICMR-NIV, Pune) and Illumina COVIDSeq RUO test kits (Illumina Inc, USA) (IISER, Pune). Sequencing was performed using GridION (ONT, Littlemore, United Kingdom), Ion S5 (ThermoFisher Scientific, Waltham, MA, USA) and the NextSeq 550 sequencing platform, respectively. Reads were aligned to the reference genome using MinKNOW software, Iterative Refinement Meta-Assembler (IRMA) and DRAGEN COVID Lineage application, respectively. Lineage analysis was done using Phylogenetic Assignment of Named Global Outbreak LINeages (PangoLIN) COVID-19 lineage assigner, version v4.1.3, pangolin-data version v1.17, and clade was analysed using Nextclade software, version v2.9.1.

2.3 Demographic and Clinical Data Collection

A set of demographic data, including the patient's age, gender, area of residence, contact number, and date of specimen collection and testing, were collected from the centralised data entry portal for COVID-19 testing in India, the ICMR COVID-19 Data Portal using the unique identification number (ICMR ID). In order to gather additional information, telephonic interviews were conducted, and patients were interviewed individually. During the interview, the demographic details available on the portal were validated, and information on the presence of any symptoms at the time of testing, comorbidities, vaccination details, history of the previous infection, hospitalisation, oxygen requirement and treatment were collected. Patients unwilling to share their history during the interview were excluded from the study.

2.4 Statistical Analysis

All demographic and clinical data were recorded using Microsoft[®] Excel, and analysis was performed using Microsoft[®] Excel and Epi InfoTM, version 7.2.4.0. The continuous variables were presented as the median and interquartile range (IQR). The Kruskal-Wallis test was performed to compare the median values between the variants. The categorical variables were presented as numbers and percentages. The Chi-square test was used to compare categorical variables between the variants. Fisher's exact test compared the categorical values with limited data. A *p*-value < 0.05 was considered statistically significant.

3. RESULTS

3.1 Demographic Characteristics of the Study Population

Between 10th July 2022 and 12th January 2023, 1141 RT-PCR-positive SARS-CoV-2 samples were collected and included in the study. *Table 1* describes the geographical distribution of the samples collected. The study population included cases from all age groups with a median age of 37 years (IQR: 28-57) (*Table 2*). The male-to-female ratio was 1.22:1 (*Table 3*).

Area of I	Residence	Frequency	Percentage	95% LCL	95% UCL	
	Ahmednagar	7	0.61%	0.30%	1.26%	
	Akola	4	0.35%	0.14%	0.90%	
	Alibag	17	1.49%	0.93%	2.37%	
	Amravati	5	0.44%	0.19%	1.02%	
	Aurangabad	4	0.35%	0.14%	0.90%	
	Beed	11	0.96%	0.54%	1.72%	
	Buldhana	2	0.18%	0.05%	0.64%	
	Jalgaon	2	0.18%	0.05%	0.64%	
	Jalna	7	0.61%	0.30%	1.26%	
Maharashtra	Kolhapur	94	8.24%	6.78%	9.98%	
IVIdi i di distitu d	Mumbai	76	6.66%	5.35%	8.26%	
	Nagpur	1	0.09%	0.02%	0.49%	
	Nanded	1	0.09%	0.02%	0.49%	
	Nashik	2	0.18%	0.05%	0.64%	
	Osmanabad	2	0.18%	0.05%	0.64%	
	Pune	801	70.20%	67.48%	72.78%	
	Satara	13	1.14%	0.67%	1.94%	
	Solapur	1	0.09%	0.02%	0.49%	
	Thane	73	6.40%	5.12%	7.97%	
	Washim	1	0%	0.02%	0.49%	
Outside	Goa	15	1.31%	0.80%	2.16%	
Maharashtra	Silavasa	2	0.18%	0.05%	0.64%	
то	TAL	1141	100%			

Table 1: Geographical distribution of 1141 RT-PCR-positive SARS-CoV-2 samples

Table 2: Age-wise distribution of 1141 RT-PCR-positive SARS-CoV-2 samples

Age Groups (in years)	Frequency	Percentage	95% LCL	95% UCL	
0 - <10	23	2.02%	1.35%	3.01%	
10 - <20	49	4.29%	3.26%	5.63%	
20 - <30	252	22.09%	19.77%	24.58%	
30 - <40	288	25.24%	22.81%	27.84%	
40 - <50	125	10.96%	9.27%	12.90%	
50 - <60	147	12.88%	11.06%	14.95%	
60 - <70	126	11.04%	9.35%	12.99%	
70 - <80	94	8.24%	6.78%	9.98%	
80 - <90	37	3.24%	2.36%	4.44%	
TOTAL	1141	100%			

Gender	Frequency	Percentage	95% LCL	95% UCL	
Female	515	45.14%	42.27%	48.03%	
Male	626	54.86%	51.97%	57.73%	
TOTAL	1141	100%			

Table 3: Gender-wise distribution of 1141 RT-PCR-positive SARS-CoV-2 samples

3.2 SARS-CoV-2 Lineage Distribution in Sequenced Samples

Of the 1141 samples sequenced, 911 (79.84%) were assigned Pango lineages, of which the BA.2.75* (63.78%) was the predominant Omicron variant, followed by the XBB* (18.88%), BA.2.38* (4.94%), BA.5* (4.06%), BA.2.10* (3.51%) and BQ.1* (1.65%) (*Table 4*). *Figure 1* describes the temporal distribution of SARS-CoV-2 variants detected during the study period. The x-axis represents the calendar weeks, and the y-axis represents the percentage of each lineage from the sequenced samples.


Nextclade Clade Assigned	Pangolin Lineage	s Assigned	Numt	oers (%)	
21K	B.1.1.529		01 (0	0.09%)	
21L	BA.2		12 (1	L.05%)	
	BA.2.10		01 (0.09%)		
21L	BA.2.10.1	BA.2.10*	26 (2.28%)	32 (2.80%)	
211	BA.2.10.4	DA.2.10	04 (0.35%)	52 (2.80%)	
	BJ.1		01 (0.09%)		
22C	BA.2.12.1		01 (0	0.09%)	
	BA.2.3.20		02 (0	0.18%)	
	BA.2.38		03 (0.26%)		
	BA.2.38.1	BA.2.38*	02 (0.18%)	45 (3.94%)	
21L	BA.2.38.2		03 (0.26%)		
	BA.2.38.3		01 (0.09%)		
	BH.1		36 (3.16%)		
21L	BA.2.74		02 (0	0.18%)	
	BA.2.75		93 (8.15%)		
	BA.2.75.1		69 (6.05%)		
	BA.2.75.2		109 (9.55%)		
	BA.2.75.3		07 (0.61%)		
22D	BA.2.75.5	BA.2.75*	05 (0.44%)	581 (50.92%)	
220	BA.2.75.6	DA.2.75	14 (1.23%)	561 (50.52%)	
	BA.2.75.7		17 (1.49%)	-	
	BA.2.75.9		01 (0.09%)		
	BL.1		36 (3.16%)		
	BL.2]	13 (1.14%)		

Table 4: Variant distribution among the 1141 SARS-CoV-2 samples sequenced

	BL.3		02 (0.18%)	
	BM.1		13 (1.14%)	
	BM.1.1		63 (5.52%)	
	BM.1.1.1		04 (0.35%)]
	BM.1.1.3		09 (0.79%)	
	BM.4.1		06 (0.53%)	
	BM.4.1.1		17 (1.49%)	
	BN.1		29 (2.54%)	
	BN.1.1		01 (0.09%)	
	BN.1.3		02 (0.18%)	
	BN.1.3.1		02 (0.18%)	
	BN.1.4		09 (0.79%)	
	BR.2.1		02 (0.18%)	
	BY.1		43 (3.77%)	
	CA.2	7	01 (0.09%)	1
	CA.3		02 (0.18%)	
	CH.1		01 (0.09%)	
	CH.1.1		11 (0.96%)	
21L	BA.2.76		07 (0	0.61%)
21L	BA.2.83		01 (0	0.09%)
	BA.5		02 (0.18%)	
	BA.5.2		11 (0.96%)	
	BA.5.2.1		06 (0.53%)	
	BA.5.6		01 (0.09%)	
	BA.5.9		01 (0.09%)	
	BE.1.1		03 (0.26%)	
22B	BF.7	BA.5*	03 (0.26%)	37 (3.24%)
220	BF.7.6		01 (0.09%)	
	BF.14		01 (0.09%)]
	BF.26		03 (0.26%)	
	BF.27		01 (0.09%)	
	BF.3		03 (0.26%)]
	BF.33		01 (0.09%)	
	BQ.1		02 (0.18%)	
	BQ.1.1		05 (0.44%)	
	BQ.1.1.18		01 (0.09%)	
22E	BQ.1.1.22	BQ.1*	01 (0.09%)	15 (1.31%)
	BQ.1.1.4		01 (0.09%)] ` ´
	BQ.1.2		02 (0.18%)]
	BQ.1.9		03 (0.26%)	
	XAR	Recombinant	01 (0	0.09%)
	XBF	Recombinant	02 (0	D.18%)
22F	XBB		70 (6.13%)	
	XBB.1	XBB*	41 (3.59%)	172 (15.07%)
	XBB.1.5		07 (0.61%)	

	XBB.2	31 (2.72%)	
	XBB.3	22 (1.93%)	
	XBB.5	01 (0.09%)	
Not Assigned	Not Assigned	230 (20.16%)	
Not Assigned	(QC Failure)		
Grand Total		1141	(100%)

Figure 1: Temporal distribution of SARS-CoV-2 variants during the study period (From 10th July 2022 to 12th January 2023)



3.3 Demographic and clinical characteristics of major SARS-CoV-2 variants detected during the study

Table 5 describes the demographic characteristics of the major SARS-CoV-2 variants detected in the study. Out of 882 cases, there were 475 (53.85%) males and 407 (46.15%) females. The median age of cases infected with BA.2.10* was 29.5 years, BQ.1* was 55.0 years, XBB* was 38.5 years, and for BA.2.38*, BA.2.75*, BA.5* variants, it was 38.0 years. There was a statistically significant difference in the median age (*p*-value = 0.030) of cases infected with different variants. *Figure 2* depicts the distribution of major variants and the area of residence of cases.

Table 5: Demographic characteristics of major SARS-CoV-2 variants detected during the study period (n=882)

	BA.2.10*	BA.2.38*	BA.2.75*	BA.5*	BQ.1*	XBB*	Grand Total		
1. Gender-wise distributionp - value = 0.088									
Mala	22	19	311	15	10	98	475		
Male	(68.75%)	(42.22%)	(53.53%)	(40.54%)	(66.67%)	(56.98%)	(53.85%)		
Famala	10	26	270	22	05	74	407		
Female	(31.25%)	(57.78%)	(46.47%)	(59.46%)	(33.33%)	(43.02%)	(46.15%)		
2. Median	Age		·	·		H (5) = 12.34	13, <i>p</i> -value = 0.030		
	29.5	38.0	38.0	38.0	55.0	38.5			
	(IQR: 20.5	(IQR: 29.0	(IQR: 28.0	(IQR: 31.0	(IQR: 41.0	(IQR: 28.5			
	- 43.0)	- 58.0)	- 57.0)	- 59.0)	- 71.0)	– 59.0)			
3. Age-wise	e distributio	n							
0 (10	01	00	11	01	00	03	16		
0 - <10	(3.13%)	(00%)	(1.89%)	(2.70%)	(00%)	(1.74%)	(1.81%)		
10 (20	07	04	25	00	00	11	47		
10 - <20	(21.88%)	(8.89%)	(4.30%)	(00%)	(00%)	(6.40%)	(5.33%)		
20 (20	08	08	133	06	01	32	188		
20 - <30	(25.00%)	(17.78%)	(22.89%)	(16.22%)	(6.67%)	(18.60%)	(21.32%)		
30 - <40	04	11	140	13	02	42	212		
50 - <40	(12.50%)	(24.44%)	(24.10%)	(35.14%)	(13.33%)	(24.42%)	(24.04%)		
40 - <50	05	06	53	03	04	21	92		
40 - <50	(15.63%)	(13.33%)	(9.12%)	(8.11%)	(26.67%)	(12.21%)	(10.43%)		
50 - <60	01	05	86	07	02	22	123		
50 - <60	(3.13%)	(11.11%)	(14.80%)	(18.92%)	(13.33%)	(12.79%)	(13.95%)		
60 - <70	05	04	64	05	02	18	98		
0070	(15.63%)	(8.89%)	(11.02%)	(13.51%)	(13.33%)	(10.47%)	(11.11%)		
70 - <80	01	06	48	02	03	18	78		
70 - \00	(3.13%)	(13.33%)	(8.26%)	(5.41%)	(20.00%)	(10.47%)	(8.84%)		
80 - <90	00	01	21	00	01	05	28		
00 - 50	(00%)	(2.22%)	(3.61%)	(00%)	(6.67%)	(2.91%)	(3.17%)		




Figure 2: Distribution of major SARS-CoV-2 variants detected during the study versus the area of residence

Of the 882 cases, 540 (61.22%) could be telephonically contacted to obtain information regarding their symptoms, hospitalisation, treatment and vaccination status. **Table 6** summarises the clinical characteristics, vaccination status and outcome of 494 cases. Most cases were symptomatic (91.48%) with mild symptoms. Fever (77.73%) was the most common symptom across all variants, followed by cold and rhinorrhoea (47.98%), cough (42.31%), myalgia and fatigue (18.83%). Of the 540 cases, 478 (88.52%) cases confirmed the presence of no comorbidity. Among those with one or more comorbid conditions, diabetes mellitus was the most common condition reported (51.61%), followed by hypertension (50%), carcinoma (8.06%), coronary heart disease (6.45%), liver and kidney disease (4.84%), asthma (4.84%) tuberculosis and arthritis (3.23% each). There was a statistically significant difference between the absence or presence of comorbidity and the outcome of disease (*p*-value=<0.001) (*Figure 3*). There were 414 (76.67%) cases who required home isolation, and 126 (23.33%) cases were institutionally quarantined/hospitalised. Of the 540 cases, 3.15% recovered without any treatment, 87.96% recovered with supportive treatment, 6.67% required oxygen therapy and 2.22% were given antiviral treatment. There were 16 (2.96%)

cases who succumbed to the disease, and the rest (97.04%) survived. *Figure 4* depicts the age-wise distribution of survived and dead cases.


Table 6: Clinical Characteristics and outcome of 540 patients infected with major variants
<u>(n=540)</u>


	BA.2.10*	BA.2.38*	BA.2.75*	BA.5*	BQ.1	XBB*	Grand Total					
Total number of cases with history available												
	17	21	374	18	10	100	540					
	(53.13%)	(46.67%)	(64.37%)	(48.65%)	(66.67%)	(58.14%)	(61.22%)					
History of previous COVID-	19 infection	1		1	1	<i>p</i> - valu	ue = 0.259					
	01	03	51	00	01	15	71					
	(5.88%)	(14.29%)	(13.64%)	(00%)	(10%)	(15%)	(13.15%)					
Symptom status at the tim	e of sample	collection	<u> </u>	1	1	<i>p</i> - valu	ue = 0.071					
Asymptomatic	03	01	28	00	03	11	46					
	(17.65%)	(4.76%)	(7.49%)	(00%)	(30%)	(11.%)	(8.52%)					
Symptomatic	14	20	346	18	07	89	494					
	(82.35%)	(95.24%)	(92.51%)	(100%)	(70%)	(89%)	(91.48%)					
Presence of comorbidity						<i>p</i> - val	ue = 0.145					
No comorbidity	17	15	334	17	10	85	478					
	(100%)	(71.43%)	(89.30%)	(94.44%)	(100%)	(85%)	(88.52%)					
Presence of one condition	00	05	27	01	00	11	44					
	(00%)	(23.81%)	(7.22%)	(5.56%)	(00%)	(11%)	(8.15%)					
Presence of two or more conditions	00	01	13	00	00	04	18					
	(00%)	(4.76%)	(3.48%)	(00%)	(00%)	(4%)	(3.33%)					
Initial presenting symptom	S		L	ı	·	ı						
Fever	08	16	277	13	05	65	384					
	(57.14%)	(80%)	(80.06%)	(72.22%)	(71.43%)	(73.03%)	(77.73%)					
Cough	05	13	146	07	04	34	209					
	(35.71%)	(65%)	(42.20%)	(38.89%)	(57.14%)	(38.20%)	(42.31%)					

Eatique / Weakposs	00	02	78	02	01	10	93
Fatigue/ Weakness	(00%)	(10%)	(22.54%)	(11.11%)	(14.29%)	(11.24%)	(18.83%)
Myalgia	03	00	74	01	02	13	93
	(21.43%)	(00%)	(21.39%)	(5.56%)	(28.57%)	(14.61%)	(18.83%)
Cold and Rhinorrhoea	07	06	163	11	03	47	237
	(50%)	(30%)	(47.11%)	(61.11%)	(42.86%)	(52.81%)	(47.98%)
Headache	00	02	26	00	02	10	40
	(00%)	(10%)	(7.51%)	(00%)	(28.57%)	(11.24%)	(8.10%)
Diarrhoea	00	00	05	02	00	03	10
	(00%)	(00%)	(1.45%)	(11.11%)	(00%)	(3.37%)	(2.02%)
Breathlessness	00	02	22	00	01	06	31
Dieathessness	(00%)	(10%)	(6.36%)	(00%)	(14.29%)	(6.74%)	(6.28%)
Vomiting	00	00	09	00	00	02	11
, on the second s	(00%)	(00%)	(2.60%)	(00%)	(00%)	(2.25%)	(2.42%)
Sore throat	01	01	15	01	02	16	36
	(7.14%)	(5%)	(4.34%)	(5.56%)	(28.57%)	(17.98%)	(7.29%)
Skin rash	00	00	03	00	00	00	03
	(00%)	(00%)	(0.87%)	(00%)	(00%)	(00%)	(0.61%)
Chest pain	00	00	01	00	00	00	01
	(00%)	(00%)	(0.29%)	(00%)	(00%)	(00%)	(0.20%)
Loss of taste	00	00	02	00	00	02	04
	(00%)	(00%)	(0.58%)	(00%)	(00%)	(2.25%)	(0.81%)
Loss of smell	00	00	02	00	00	01	03
	(00%)	(00%)	(0.58%)	(00%)	(00%)	(1.12%)	(0.61%)
Type of Quarantine						p - valu	e = 0.163
	16	14	280	15	09	80	414
Home quarantine	(94.12%)	(66.67%)	(74.87%)	(83.33%)	(90%)	(80%)	(76.67%)
	01	07	04	02	01	20	100
Institutional quarantine/	01 (5.88%)	07 (33.33%)	94 (25.13%)	03 (16.67%)	01 (10%)	20 (20%)	126 (23.33%)
required hospitalisation	. ,	· · · /	, ,	· /	· · /	, ,	,

Treatment						<i>p</i> - val	ue = 0.067
	03	00	10	00	00	04	17
No treatment taken	(17.65%)	(00%)	(2.67%)	(00%)	(00%)	(4%)	(3.15%)
Need for conservative	13	17	330	18	10	87	475
treatment	(76.47%)	(80.95%)	(88.24%)	(100%)	(100%)	(87%)	(87.96%)
Need for supplemental	01	04	27	00	00	05	37
oxygen	(5.88%)	(19.05%)	(7.22%)	(00%)	(00%)	(5%)	(6.85%)
a. Low flow oxygen	01 (100%)	03 (75%)	23 (85.18%)	00 (00%)	00 (00%)	04 (80%)	31 (83.78%)
b. Intubation	00 (00%)	01 (25%)	04 (14.82%)	00 (00%)	00 (00%)	01 (20%)	06 (16.22%)
Need for antiviral							
agents/steroids or	00	00	07	00	00	04	11
immunomodulatory drugs	(00%)	(00%)	(1.87%)	(00%)	(00%)	(4%)	(2.04%)
The outcome of disease						p - valu	ie = 0.495
Survived	17 (100%)	21 (100%)	362 (96.79%)	18 (100%)	10 (100%)	96 (96%)	524 (97.04%)
Dead	00 (00%)	00 (00%)	12 (3.21%)	00 (00%)	00 (00%)	04 (4%)	16 (2.96%)
Vaccination Status						<i>p</i> - valu	ue = 0.181
Vaccinated with at least one dose	13 (76.47%)	18 (85.71%)	341 (91.18%)	15 (83.33%)	10 (100%)	94 (94%)	491 (90.93%)
a. Single Dose	00 (00%)	00 (00%)	15 (4.40%)	00 (00%)	00 (00%)	02 (2.13%)	17 (3.46%)
b. Two doses	11 (84.62%)	16 (88.89%)	238 (69.79%)	11 (73.33%)	06 (60%)	68 (72.34%)	329 (73.27%)
c. Booster Dose	02 (15.38%)	02 (11.11%)	88 (25.81%)	04 (26.67%)	04 (40%)	24 (25.53%)	104 (23.16%)
Not vaccinated	04 (23.53%)	03 (14.29%)	28 (7.49%)	03 (16.67%)	00 (00%)	03 (3%)	41 (7.59%)

Data not available	00	00	05	00	00	03	08
	(00%)	(00%)	(1.34%)	(00%)	(00%)	(3%)	(1.48%)








Figure 4: Age-wise distribution of survived and dead cases

Among the 540 cases, 491 (90.93%) were vaccinated with at least a single dose of the COVID-19 vaccine, 41 (7.59%) were unvaccinated, and for eight (1.48%) cases, vaccine data was not available. *Figure 5* enumerates the type of vaccine administered to the study population, with COVISHIELDTM (ChAdOx1 nCoV-19 Corona Virus Vaccine) (80.04%) being the most common vaccine, followed by COVAXIN® (BBV152A- a whole inactivated virus-based COVID-19 vaccine) (11.20%). *Figure 6* describes the vaccination status of the study population for the age groups. Most unvaccinated individuals fall in the age group of 0 to 10 years (25%) who were not offered vaccination as a part of the vaccination policy in the country. *Figure 7* shows the impact of vaccination on the survival of cases. Out of 532 cases with available vaccination data, 491 (92.29%) were vaccinated with at least one dose of vaccine, of which 479 (97.56%) survived, and 12 (2.44%) died. Similarly, out of 41 (7.71%) cases who were not vaccinated, 37 (90.24%) survived, and 04 died (9.76%). The impact of vaccination on the disease outcome was statistically significant, with *p*-value= 0.001.




Figure 5: Type of vaccine administered to the study population





Figure 6: Vaccination status by age groups

Figure 7: Impact of vaccination on the survival of cases



3.4 Clinical characteristics of XBB.1.5 SARS-CoV-2 variant detected during the study

Of the seven XBB.1.5 cases, history was available for six cases. Three out of six cases (50%) had a history of previous infection. All six cases had mild symptoms, with cold and rhinorrhoea (100%) being the most common symptom, followed by sore throat (50%), fever (66.67%) and cough (33.33%). None required hospitalisation or supplemental oxygen; all recovered with conservative treatment at home. Out of the six cases, four had a history of international travel to the United States of America (USA) and Germany, one to Gujarat, and one had contact with a positive person with a history of travel to the USA. All six cases were vaccinated with at least one dose of vaccine, of which 02 (33.33%) cases had received two doses, and 04 (66.67%) had received booster doses. No death was reported among the detected XBB.1.5 cases.

4. DISCUSSION

The SARS-CoV-2 virus is known for its unique evolutionary characteristic compared to other respiratory viruses (Figure 6). In 2022, saltation or 'variant' evolution gave rise to "second generation variants" evolving from a BA.2 lineage background that have numerous non-synonymous mutations, concentrated in the N-terminal domain (NTD) and the receptor binding domain (RBD) of the Spike protein. A few examples include BA.2.75, BA.2.10.4, BJ.1, BS.1, BA.2.3.20, BA.2.83, BP.1, and DD.1, of which BA.2.75 is the most widespread secondgeneration BA.2 variant. (9) Unlike previous dominant lineages, BA.5 accumulated potent antigenic mutations in a step-wise manner as a result of antigenic drift. The most rapidly growing sublineage of BA.5 is BQ.1, of which BQ.1.1 is the largest containing three further antigenic mutations. (9) SARS-CoV-2 virus, being a coronavirus, is prone to inter-lineage recombination. It generally occurs when a wave declines and a new variant emerges. (10) The resultant recombinant variant possesses unique advantageous properties from both parents. (11) There are 62 recombinant lineages designated by Pangolin (as of December 2022) (12), denoted by a prefix X, of which XBB is the most widespread inter-lineage recombinant to date. (9) XBB is a recombination of BJ.1 (5' part of XBB genome) and BM.1.1.1 (3' part of XBB genome) with a breakpoint between 22,897 and 22941 positions in the RBD of the spike protein (corresponding to amino acid positions 445-460). (9, 5) XBB.1.5, a rapidly growing subvariant of the XBB.1 variant, carries an additional mutation F486P in its spike protein, a rare two-nucleotide substitution compared to its parent strain. (13) Figure 7 depicts the

mutation prevalence across lineages BJ.1 and BM.1.1.1 and XBB* variant. (14) XBB is shown to have substantially higher viral fitness (Re) than its parental lineages, making it the first documented example of a SARS-CoV-2 variant with increased fitness through recombination. (15)





Figure 6: Phylogenetic relatedness and convergent evolution of newer SARS-CoV-2

lineages (9)

Figure 7: Mutation prevalence across lineages BJ.1, BM.1.1.1 and XBB* (13)






In the present study, between 10th July 2022 and 12th January 2023, BA.2.75* was the predominant Omicron variant. In India, as of 24th January 2023, the apparent cumulative prevalence of BA.2.75*, XBB*, BA.2.38*, BA.2.10*, BA.5*, BQ.1 * and XBB.1.5 is 14%, 15.68%, 7%, 17%, 4% and 3%, respectively. (16, 17, 18-20, 4, 7) Over the last 60 days, XBB.1 is the dominant lineage (17%) in the country (Figure 8). (21) XBB has also spread to countries like Oman, Dominican Republic, Malaysia, Iraq, Singapore, Indonesia and Uganda, with a prevalence of 25% to 93% in the last 60 days as on 24th January 2023. (6) On the contrary, BA.5 and its descendant lineages dominate globally, with about 70.5% of sequences submitted to GISAID between 26th December 2022 to 1st January 2023. (2) However, the prevalence of BA.5 is decreasing globally with a rise in BA.2 descendant lineages, particularly BA.2.75*. The worldwide apparent cumulative prevalence of BQ.1*, BA.5*, BA.2.75*, XBB * and XBB.1.5 is 2%, 14%, 1%, 2.48% and 1%, respectively (as of 24th January 2023). (4, 20, 16, 17, 7) The regional difference in the prevalence of XBB and BQ.1 lineages, XBB being more dominant in the eastern hemisphere and BQ.1 in the western hemisphere, may be due to the proximity of these regions to places where these lineages originated. (15) However, the recently detected XBB.1.5 variant is shown to have growth advantage over other circulating Omicron sublineages, and has already been reported from 46 countries. (7) As of 24th January 2023, a total 9,173 sequences have been deposited on GISAID with the majority of sequences from the USA (74.63%), United Kingdom (9.55%), Canada (3.02%), Austria (2.57%) and Denmark (2.02%). (22)

Figure 8: Prevalence of common lineages in India over the last 60 days





The most remarkable feature of XBB is its profound resistance to humoral immunity induced by infections with prior Omicron variants. In-vitro studies have shown that XBB exhibited 30-fold and 13-fold resistance to BA.2 and BA.5 infection sera. (15) Similar findings were reported by Wang Q et al., where XBB was ~63-fold and ~49-fold more resistant to neutralisation than BA.2 and BA.4/5, respectively. (5) Several NTD and RBD spike mutations like V83A, Y144del, Q183E, R346T, L368I, V445P, F486S and F490S cooperatively contribute to resistance against humoral immunity induced by BA.2 infections. Similarly, two mutations, Y144del and G446S, were suggested to contribute to resistance against humoral immunity induced by BA.5 infections. The humoral immune-escape property of XBB.1.5 was comparable to XBB.1. (13) Spike mutations in the RBD (R346T, L368I and N460K) and NTD (V83A) are also responsible for increased ACE2 binding affinity, viral infectivity and fusogenicity of XBB compared to BA.2, BA.5 and BA.2.75 Omicron variants. (15) Deep mutational scanning studies have shown that due to the presence of additional Ser486Pro mutation in the spike protein, XBB.1.5 had a stronger binding affinity to ACE2 receptors than XBB.1, thereby explaining its significant growth advantage over XBB.1. (13) XBB-infected hamster sera showed a remarkable antiviral effect against XBB only, suggesting XBB is antigenically distinct from other Omicron subvariants. (15)

Several clinically authorised therapeutic monoclonal antibodies (mAbs) like bamlanivimab, etesevimab, imdevimab, casirivimab, tixagevimab, cilgavimab, and sotrovimab have been rendered ineffective by previous SARS-CoV-2 variants, leaving bebtelovimab as the only monoclonal antibody active against the circulating strains. However, due to mutations like N460K, F486S, R346T, V455P, G446S and F490S, XBB and its descendant XBB.1 are pan-resistant to RBD class I, II and III antibodies. (5) Also, bebtelovimab (LY-CoV1404) and Evusheld (a combination of COV2-2196 and COV2-2130) were found to be inactive against XBB/XBB.1 (5) and XBB.1.5 (13). Although XBB.1.5 escapes neutralising antibody responses, a study by Lasrado N et al. has shown that the cross-reactive T-cell responses may continue to protect against severe disease. (23) Therefore, due to immune-escape-associated and infectivity-enhancing mutations, the XBB* and XBB.1.5 variants can eventually spread worldwide. (15)

The present study suggests that the pathogenicity of XBB is comparable to that of other Omicron variants. These findings are consistent with an in-vivo study in hamsters where the XBB variant was less pathogenic than the Delta variant and had a comparable pulmonary function and viral RNA load to BA.2.75 infected hamsters. The intrinsic pathogenicity of the XBB variant and its efficiency of infecting lungs was comparable to or even lower than the BA.2.75. (15) Similarly, the seven XBB.1.5 cases detected had mild symptoms. However, it remains unclear whether the intrinsic pathogenicity of the virus or the immunity from vaccination and previous infection is responsible for mild cases in India. More clinical data from other clinical settings with different levels of immunity will help understand the behaviour of the XBB* variant.

5. CONCLUSION

To conclude, while it is encouraging that the infection caused by the SARS-CoV-2 XBB recombinant variant tends to be less severe and similar to that of other Omicron subvariants, the fact that this variant is more transmissible and immune-evasive is a cause of concern. In addition to the ongoing surveillance efforts to track the spread of new variants, our findings emphasise the importance and the need to monitor the clinical severity of infections caused by new variants. Such findings are essential for making decisions about deploying interventions and preparing healthcare systems to respond to outbreaks.

ACKNOWLEDGEMENT

We thank Mrs Poonam Pacharne, Mr Vishal Rajput and Mrs Reena Katke from Byramjee Jeejeebhoy Government Medical College and Sassoon General Hospitals, Pune; Miss Aditi and

Miss Pratiksha from ICMR-National Institute of Virology, Pune, for their technical help during the study.

COMPETING INTEREST STATEMENT

The authors have declared no competing interests.

FUNDING STATEMENT

This study did not receive any funding.

REFERENCES

- Kurhade C, Zou J, Xia H, Liu M, Chang HC, Ren P, et al. Low neutralisation of SARS-COV-2 omicron BA.2.75.2, BQ.1.1, and XBB.1 by 4 doses of parental mrna vaccine or a BA.5bivalent booster. Nature Medicine. 2022;3–18.Available from: <u>https://doi.org/10.1038/s41591-022-02162-x</u>
- World Health Organization. COVID-19 Weekly Epidemiological Update. 19th January 2023;1-13.Available from: <u>https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19---19-january-2023</u>
- Callaway E. COVID' Variant Soup' is making winter surges hard to predict. Nature.2022;611:213-214.Available from: <u>https://www.nature.com/articles/d41586-022-03445-</u>

6#:~:text=Descendants%20of%20Omicron%20are%20proliferating,coming%20up%2 Oagain%20and%20again.&text=Some%20call%20it%20a%20swarm,to%20it%20as%2 Ovariant%20soup.

- Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. BQ.1* Omicron (BQ.1.X) Variant Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available from: <u>https://outbreak.info/situationreports/BQ.1*%20%5BOmicron%20(BQ.1.X)%5D?selected=IND&loc=USA&loc=USA US-CA&loc=IND&overlay=false</u>
- Wang Q, Iketani S, Li Z, Liu L, Guo Y, Huang Y, et al. Alarming antibody evasion properties of rising SARS-COV-2 BQ and XBB subvariants. Cell. 2022;1–18.Available from: <u>https://doi.org/10.1016/j.cell.2022.12.018</u>
- Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. XBB.1 Lineage Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available

> from:<u>https://outbreak.info/situation-reports?xmin=2022-07-25&xmax=2023-01-</u> 25&pango=XBB.1

- Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. XBB.1.5* Lineage Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available from:<u>https://outbreak.info/situation-</u> <u>reports/XBB.1.5*%20%5BOmicron%20(XBB.1.5.X)%5D?xmin=2022-07-</u> 25&xmax=2023-01-25
- Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY. Clinical outcomes associated with Omicron (B.1.1.529) variant and BA.1/BA.1.1 or BA.2 subvariant infection in Southern California. Nature Medicine. 2022;28:1933–43.Available from: <u>https://doi.org/10.1038/s41591-022-01887-z</u>
- Roemer C, Hisner R, Frohberg N, Sakaguchi H, Gueli F, Peacock TP. SARS-CoV-2 evolution, post-Omicron [Internet]. Virological.2022 [Accessed on 30th December 2022].Available from: <u>https://virological.org/t/sars-cov-2-evolution-post-omicron/911</u>
- Jackson B, Boni MF, Bull MJ, Colleran A, Colquhoun RM, Darby AC, et al. Generation and transmission of interlineage recombinants in the SARS-CoV-2 pandemic. Cell. 2021;184(20):5179-5188.
- Simon-Loriere E, Montagutelli X, Lemoine F, Donati F, Touret F, Bourret J, et al. Rapid characterisation of a Delta-Omicron SARS-CoV-2 recombinant detected in Europe. Research Square (preprint). 2022.Available from: <u>https://doi.org/10.21203/rs.3.rs-1502293/v1</u>
- Release pango designations V1.17 · COV-lineages/pango-designation [Internet].
 GitHub. [Accessed on 02nd January 2023].Available from: <u>https://github.com/cov-lineages/pango-designation/releases/tag/v1.17</u>
- 13. Yue C, Song W, Wang L, Jian F, Chen X, Gao F, et al. Enhanced transmissibility of XBB.1.5 is contributed by both strong ace2 binding and antibody evasion. bioRxiv. 2023;1–4. Available from: <u>https://doi.org/10.1101/2023.01.03.522427</u>
- 14. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. Lineage Comparison [Internet]. outbreak.info; [Accessed on 2nd January 2023].Available from: <u>https://outbreak.info/compare-</u>

lineages?pango=BJ.1&pango=BM.1.1.1&pango=XBB&pango=XBB.1&pango=XBB.1.1&pango=

XBB.1.3&pango=XBB.1.4&pango=XBB.1.4.1&pango=XBB.1.5%2a%20%5BOmicron%20%28XBB.1.5.X%29%5D&pango=XBB.2&pango=XBB.3&pango=XBB.3.1&pango=XBB.4&pango=XBB.5&gene=S&threshold=75&nthresh=1&sub=false&dark=false

- Tamura T, Ito J, Uriu K, Zahradnik J, Kida I, Nasser H, et al. Virological characteristics of the SARS-COV-2 XBB variant derived from recombination of two omicron subvariants. bioRix. 2022;1–47. Available from: <u>https://doi.org/10.1101/2022.12.27.521986</u>
- 16. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. BA.2.75* [Omicron (BA.2.75.X)] Variant Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available from: <u>https://outbreak.info/situationreports/BA.2.75*%20%5BOmicron%20(BA.2.75.X)%5D?selected=IND&loc=USA&loc=USA_US -CA&loc=IND&overlay=false</u>
- 17. XBB* (Nextclade)-India [Internet]. covSPECTRUM; [Accessed on 24th January 2023].
 Available from: <u>https://cov-</u>

spectrum.org/explore/India/AllSamples/Past6M/variants?nextcladePangoLineage=XBB*&

18. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. BA.2.38 Lineage Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available from:<u>https://outbreak.info/situation-</u>

reports?pango=BA.2.38&selected=IND&loc=USA&loc=USA_US-CA&loc=IND&overlay=false

- 19. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. BA.2.10 Lineage Report [Internet]. outbreak.info; [Accessed on 24th January 2023]. Available from:<u>https://outbreak.info/situation-</u> reports?pango=BA.2.10&selected=IND&loc=USA&loc=USA_US-CA&loc=IND&overlay=false
- 20. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. BA.5*
 [Omicron (BA.5.X)] Variant Report [Internet]. outbreak.info; [Accessed on 24th January 2023]. Available from:

https://outbreak.info/situation-reports/BA.5*%20%5BOmicron%20(BA.5.X)%5D

21. Gangavarapu K, Latif AA, Mullen J, Alkuzweny M, Hufbauer E, Tsueng G, et al. India Variant Report [Internet]. outbreak.info; [Accessed on 24th January 2023].Available from:

https://outbreak.info/location-reports?xmin=2022-07-24&xmax=2023-01-24&loc=IND

- 22. XBB.1.5* (Nextclade)-World [Internet]. covSPECTRUM; [Accessed on 24th January 2023]. Available from: <u>https://cov-spectrum.org/explore/World/AllSamples/from=2022-10-01&to=2023-01-25/variants?nextcladePangoLineage=XBB.1.5*&</u>
- 23. Lasrado N, Collier A-ris, Miller J, Hachmann N, Liu J, Sciacca M, et al. Waning immunity against XBB.1.5 following bivalent mrna boosters. bioRxiv. 2023;1–5. Available from: https://doi.org/10.1101/2023.01.22.525079